BioArctic AB (publ) (BRCTF)
USD 15.67
(0.0%)
USD 15.67
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.97 Million SEK | -50.4% |
| 2022 | 10.03 Million SEK | -36.77% |
| 2021 | 15.87 Million SEK | -23.55% |
| 2020 | 20.76 Million SEK | -24.11% |
| 2019 | 27.36 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 59.7 Million SEK | 1282.06% |
| 2024 Q1 | 4.32 Million SEK | -13.24% |
| 2023 Q3 | 3.04 Million SEK | -50.16% |
| 2023 Q1 | 7.92 Million SEK | -21.11% |
| 2023 FY | 4.97 Million SEK | -50.4% |
| 2023 Q2 | 6.11 Million SEK | -22.77% |
| 2023 Q4 | 4.97 Million SEK | 63.3% |
| 2022 Q1 | 14.16 Million SEK | -10.78% |
| 2022 Q4 | 10.03 Million SEK | -1.24% |
| 2022 Q2 | 12.2 Million SEK | -13.88% |
| 2022 FY | 10.03 Million SEK | -36.77% |
| 2022 Q3 | 10.16 Million SEK | -16.68% |
| 2021 FY | 15.87 Million SEK | -23.55% |
| 2021 Q4 | 15.87 Million SEK | -10.87% |
| 2021 Q3 | 17.81 Million SEK | -7.4% |
| 2021 Q2 | 19.23 Million SEK | -0.99% |
| 2021 Q1 | 19.43 Million SEK | -6.44% |
| 2020 Q2 | 22.93 Million SEK | -6.69% |
| 2020 Q3 | 22.02 Million SEK | -3.97% |
| 2020 Q4 | 20.76 Million SEK | -5.71% |
| 2020 FY | 20.76 Million SEK | -24.11% |
| 2020 Q1 | 24.58 Million SEK | -10.18% |
| 2019 Q4 | 27.36 Million SEK | -3.86% |
| 2019 Q2 | 29.99 Million SEK | -4.8% |
| 2019 Q1 | 31.5 Million SEK | 0.0% |
| 2019 Q3 | 28.46 Million SEK | -5.1% |
| 2019 FY | 27.36 Million SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 87.916% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -20.792% |
| SQZ Biotechnologies Company | 27.47 Million USD | 81.875% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 88.521% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 83.274% |
| Mesoblast Limited | 118.7 Million USD | 95.805% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -425.061% |
| Genus plc | 233.1 Million USD | 97.864% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -69.909% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -270.576% |
| Marizyme, Inc. | 18.71 Million USD | 73.399% |
| ContraFect Corporation | 2.88 Million USD | -72.822% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -563.867% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -3574.891% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -244.253% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -114.063% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 12.006% |
| MultiCell Technologies, Inc. | 202.58 USD | -2457694.452% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 91.339% |
| EV Biologics, Inc. | 1.49 Million USD | -233.099% |
| Q BioMed Inc. | 4.1 Million USD | -21.144% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 84.958% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -690.221% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -305.337% |
| Biomind Labs Inc. | 735.54 Thousand USD | -576.916% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 97.098% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 61.691% |
| Skye Bioscience, Inc. | 4.61 Million USD | -7.881% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -460.658% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -3418.28% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 15.195% |
| IMV Inc. | 28.88 Million USD | 82.762% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -19259.229% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -120.468% |
| GB Sciences, Inc. | 1.75 Million USD | -183.009% |
| Alpha Cognition Inc. | 1.22 Million USD | -307.99% |
| HST Global, Inc. | 98.31 Thousand USD | -4964.128% |
| CSL Limited | 12.18 Billion USD | 99.959% |
| Halberd Corporation | 150 Thousand USD | -3219.333% |
| Enzolytics Inc. | 996.33 Thousand USD | -399.73% |
| Resverlogix Corp. | 6.49 Million USD | 23.294% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -942.723% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1848.027% |
| argenx SE | 20 Million USD | 75.105% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 89.072% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -83.815% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -48594.377% |
| Genscript Biotech Corporation | 417.73 Million USD | 98.808% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -2381.856% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -107.655% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -2071.476% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 92.639% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -64.53% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1284.171% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 75.507% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -3249.389% |
| BioStem Technologies, Inc. | 4.71 Million USD | -5.679% |
| ONE Bio Corp. | 19.71 Million USD | 74.745% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1890.151% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1901.849% |
| Agentix Corp. | 50 Thousand USD | -9858.0% |
| LadRx Corporation | 33.6 Thousand USD | -14715.807% |
| Cell Source, Inc. | 9.25 Million USD | 46.197% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -558.42% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -558.42% |
| NovAccess Global Inc. | 2.19 Million USD | -126.331% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 29.604% |
| Itoco Inc. | 228.37 Thousand USD | -2080.167% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -2259.995% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 0.08% |
| Kadimastem Ltd | 891.22 Thousand USD | -458.669% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1139.023% |
| CytoDyn Inc. | 30.07 Million USD | 83.445% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -928.116% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -1315.104% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 36.33% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -3964.49% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1506.129% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -5.147% |
| International Stem Cell Corporation | 4.17 Million USD | -19.172% |
| Bioxytran, Inc. | 1.92 Million USD | -158.649% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -7877.505% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -128.3% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 40.127% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 42.003% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -220.094% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1757.836% |
| Neutra Corp. | 54.15 Thousand USD | -9093.81% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -172.077% |
| PureTech Health plc | 25.51 Million USD | 80.484% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -306.706% |
| IXICO plc | 472.02 Thousand USD | -954.821% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 67.879% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 92.003% |
| CSL Limited | 12.18 Billion USD | 99.959% |
| Cellectis S.A. | 92.77 Million USD | 94.633% |